Comparative Pharmacology
Head-to-head clinical analysis: BENZTHIAZIDE versus HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZTHIAZIDE versus HYDROCHLOROTHIAZIDE.
BENZTHIAZIDE vs HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium reabsorption and increasing excretion of water, sodium, chloride, potassium, and hydrogen ions. Also causes vasodilation via direct arteriolar relaxation.
Thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing reabsorption of sodium and chloride, leading to increased excretion of water and electrolytes.
Adults: 25-50 mg orally once daily initially, may increase to 100 mg daily in a single dose or two divided doses. Maximum dose: 100 mg/day.
Oral: 25-100 mg daily in 1-2 divided doses. Maximum dose 200 mg/day.
None Documented
None Documented
Clinical Note
moderateHydrochlorothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digoxin."
Clinical Note
moderateHydrochlorothiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digitoxin."
Clinical Note
moderateHydrochlorothiazide + Deslanoside
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Deslanoside."
Clinical Note
moderateTerminal elimination half-life: 8-12 hours; clinical context: supports once-daily dosing for hypertension, but duration of action may extend beyond half-life due to tissue distribution.
Terminal elimination half-life is 5.6–14.8 hours (mean ~9 hours). In patients with renal impairment (CrCl <30 mL/min), half-life is prolonged up to 24–48 hours, necessitating dose adjustment.
Renal: ~90% (60% unchanged, 30% as glucuronide conjugate); biliary/fecal: minimal (<5%).
Primarily renal (≥95%) via glomerular filtration and tubular secretion, with approximately 60% of the dose excreted unchanged in urine. Minor biliary/fecal excretion accounts for <5%.
Category C
Category A/B
Thiazide Diuretic
Thiazide Diuretic
Hydrochlorothiazide + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Acetyldigitoxin."